

REMARKS/ARGUMENTS

After entry of this paper, claims 12, 14-15, 19-23, 25, 32-33 and 36-44 are pending. Claims 1-11, 13, 16-18, 24, 26-31, 34 and 35 are canceled. Claim 32 is amended to correct a misspelling. Claims 38-44 are newly introduced and are supported throughout the specification and by the original and pending claims. See particularly, paragraph No. 233, which indicates that inducing formation between a prey and bait protein can involve concentration and incubation time for the culture as well as by introducing signaling factors (see also paragraph Nos. 118, 119 and 337). No new matter is introduced by these claims.


In response to the species restriction, Applicants have elected as the detectable substance, the enzyme or enzymatic label; as the epitope tag, FLAG; as the source of protein sequence, any protein sequence, defined or from a random library; as the type of interaction, a protein:protein interaction, and as the induction method, the introduction of TGF β signaling that mediates the SMURF:prey protein interaction.

The generic claims are claims 12, 19, 23 and claims dependent thereon. The claims that read on these species elections are claim 38 and the claims dependent thereon. It is Applicants' understanding that if no prior art is found that negatively impacts patentability of these elected species, the generic claims will be examined.

The Director is hereby authorized to charge the extension fee of \$245 under 37 CFR § 1.17(a)(2), any deficiency in any fees due with the filing of this paper or

during the pendency of this application or credit any overpayment in any fees to our
Deposit Account No. 08-3040.

Respectfully submitted,
HOWSON & HOWSON LLP
Attorney for Applicants



Mary E. Bak
Registration No. 31,215
501 Office Center Drive
Suite 210
Fort Washington, PA 19034
Telephone: 215-540-9200
Facsimile: 215-540-5818